logo

Ultragenyx Pharmaceutical Inc (RARE)



Trade RARE now with
  Date
  Headline
1/29/2018 8:31:36 AM Ultragenyx Appoints Camille Bedrosian As Chief Medical Officer And EVP
1/23/2018 9:41:46 PM Ultragenyx Pharma Prices Public Offering Of 4.39 Mln Shares At $57.00/shr
1/22/2018 4:15:55 PM Ultragenyx Announces Proposed Public Offering Of Common Stock
1/17/2018 4:35:27 PM Wedbush Is Raising Ultragenyx Pharmaceutical Inc (RARE) FY18 Rev. Estimate To 235.8 M From 226.6 M
1/17/2018 4:35:08 PM Wedbush Is Raising Ultragenyx Pharmaceutical Inc (RARE) Q4 18 Rev. Estimate To 14.2 M From 14.0 M
1/17/2018 4:34:48 PM Wedbush Is Increasing Ultragenyx Pharmaceutical Inc (RARE) Q3 18 Rev. Estimate To 77.2 M From 74.5 M
1/17/2018 4:34:29 PM Wedbush Is Raising Ultragenyx Pharmaceutical Inc (RARE) Q2 18 Rev. Estimate To 8.0 M From 7.6 M
1/17/2018 4:34:10 PM Wedbush Is Increasing Ultragenyx Pharmaceutical Inc (RARE) Q1 18 Rev. Estimate To 136.4 M From 130.4 M
1/17/2018 4:33:54 PM Wedbush Is Increasing Ultragenyx Pharmaceutical Inc (RARE) FY17 Rev. Estimate To 1.6 M From 1.2 M
1/17/2018 4:33:38 PM Wedbush Is Raising Ultragenyx Pharmaceutical Inc (RARE) Q4 17 Rev. Estimate To 1.4 M From 1.0 M
1/17/2018 4:30:52 PM Wedbush Is Raising Ultragenyx Pharmaceutical Inc (RARE) FY18 Estimate To -4.06 From -4.43
1/17/2018 4:30:31 PM Wedbush Is Increasing Ultragenyx Pharmaceutical Inc (RARE) Q4 18 Estimate To -2.06 From -2.10
1/17/2018 4:30:08 PM Wedbush Is Raising Ultragenyx Pharmaceutical Inc (RARE) Q3 18 Estimate To -0.71 From -0.77
1/17/2018 4:29:41 PM Wedbush Is Increasing Ultragenyx Pharmaceutical Inc (RARE) Q2 18 Estimate To -2.04 From -2.08
1/17/2018 4:29:26 PM Wedbush Is Increasing Ultragenyx Pharmaceutical Inc (RARE) Q1 18 Estimate To 0.74 From 0.53
1/17/2018 4:29:10 PM Wedbush Is Increasing Ultragenyx Pharmaceutical Inc (RARE) FY17 Estimate To -7.48 From -7.49
1/17/2018 4:28:52 PM Wedbush Is Raising Ultragenyx Pharmaceutical Inc (RARE) Q4 17 Estimate To -2.26 From -2.27
1/4/2018 9:09:35 AM Ultragenyx To Provide Addl Information To FDA For Consideration Of Possible Early Filing On Current Phase 2 Data
12/18/2017 8:30:57 AM Ultragenyx Sells Priority Review Voucher For $130 Mln